Pharvaris BV (PHVS) Stock Analysis

Pharvaris BV (PHVS) is a publicly traded company in the HEALTHCARE sector. It trades at $28.98, carries a market capitalization of $2.11B. This page summarizes the public market data, fundamentals, and frequently asked questions for PHVS, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $28.98
• Market Cap: $2.11B
• EPS: $-3.16
• 52-Week High: $33.33
• 52-Week Low: $15.91

Market Sentiment

Pharvaris BV currently has a Neutral sentiment score of 0.04.

About Pharvaris BV

Pharvaris BV is a clinical-stage biopharmaceutical company headquartered in Leiden, the Netherlands, focused on developing innovative therapies for rare diseases, particularly hereditary angioedema. With a strong commitment to addressing significant unmet medical needs, the company utilizes its proprietary drug development platform to advance its therapeutic pipeline. Pharvaris aims to enhance the quality of life for patients affected by this orphan disease, positioning itself as a key player...

GNG Research Analysis

GNG Research scores Pharvaris BV (PHVS) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for PHVS.

Frequently Asked Questions

Does PHVS pay dividends?

Pharvaris BV (PHVS) does not currently pay a regular dividend.

What is PHVS's market cap?

Pharvaris BV (PHVS) has a market capitalization of $2.11B with a current stock price of $28.98.